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 Letter to Dermatology 
mab, ECP levels and eosinophil counts fell to normal values with-
in 5 months. However, the PASI increased to 10.1. Etanercept was 
introduced, and the eosinophil count was still in the normal range 
3 months later.
 Patient 2 
 A 55-year-old Caucasian female with a 13-year history of 
plaque-type psoriasis and psoriatic arthritis had failed to show 
satisfactory results after receiving anthralin, topical steroids, cal-
cineurin inhibitors, narrow-band UVB and psoralen + UVA. 
Combination treatment with adalimumab, anthralin and topical 
steroids was initiated. The complete blood count was normal. 
Over the next 11 months, the PASI fell from 7.7 to 0. After 8.5 
months of therapy, she developed eosinophilia (1,250/  l, peak-
ing at 1,480/  l;  fig.  1 b). After 3.5 months, ECP was elevated
(149   g/l). A parasite screen of a faecal specimen revealed asymp-
tomatic colonization with the facultative pathogen  Dientamoeba 
fragilis , which we decided not to treat  [5] . The total blood IgE 
level was not elevated, and tryptase was slightly elevated (14.7 
U/l). The haematological profile was normal. After a switch from 
adalimumab to methotrexate, the eosinophilia resolved within 
10 days.
 Patient 3 
 A 24-year-old Caucasian male had been consulting us for pho-
totherapy- and isotretinoin-resistant plaque psoriasis without 
joint involvement for 11 years. He had an atopic disposition and a 
history of resolved hepatitis C. With 2  ! 25 mg etanercept per 
week, the PASI fell from 15.1 to 1.9 within a year. During the first 
course of treatment, above-normal eosinophil counts  1 700/  l al-
ternated with normal values ( fig. 1 c). At a value of 830/  l, treat-
ment was temporarily withdrawn, and the eosinophil count nor-
malized. When etanercept was re-introduced, low-level eosin-
ophilia recurred (740/  l). During subsequent treatment with 
adalimumab, however, the eosinophil count rose up to 1,270/  l 
and then spontaneously resolved to values at the upper limit of the 
normal range (690/  l). No clinical findings were associated with 
these fluctuations of eosinophil counts other than the temporal 
association with the TNF-  antagonists. A parasite screen was 
normal. Total IgE levels were elevated (360 kU/l), as was ECP. The 
SX1 inhalant allergen screen was positive. Serum tryptase was not 
elevated. The haematological profile was normal. An overview of 
the clinical data of all 3 patients is shown in  table 1 . Eosinophils 
were significantly increased during treatment with adalimumab 
compared to treatment with etanercept or no biological agent 
( fig. 1 d).
 Discussion 
 The introduction of biologicals has improved treatment effi-
cacy in several chronic inflammatory disorders. Early identifica-
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 Introduction 
 Psoriasis is dependent on Th1- and Th17-polarized CD4 T 
cells that produce pro-inflammatory cytokines (such as TNF-  ) 
and thus prompt the development of acanthosis and papillomato-
sis  [1] . Blocking TNF-  greatly improves clinical outcomes  [2, 3] 
and results in fewer (and generally milder) side effects than ob-
served for older drugs (e.g. cyclosporin A or methotrexate). Com-
mon side effects are temporary headaches, nasopharyngitis, up-
per respiratory tract infections, injection site reactions, eczema 
and (more rarely) vasculitis  [4] . Here, we report on 3 patients with 
psoriasis (variously with and without joint involvement) who de-
veloped isolated eosinophilia during TNF blockade. 
 Patient 1 
 A 46-year-old Caucasian male with a 30-year history of severe 
psoriasis and psoriatic arthritis was treated with a combination of 
adalimumab, anthralin and topical steroids. Prior to treatment, 
slight eosinophilia had been noted (730/  l of blood, relative to an 
upper normal limit of 700/  l). The serum tryptase level was nor-
mal ( ! 11.7 U/l). The patient had a history of seasonal allergic rhi-
nitis but no other signs of atopy. Total IgE was  ! 100 kU/l. Prior to 
initiation of adalimumab treatment, the patient had a Psoriasis 
Area and Severity Index (PASI) score of 11.3, which fell to 0.1 after 
4.5 months of treatment. After 3.25 months of therapy, he devel-
oped eosinophilia (1,550/  l;  fig. 1 a). Eosinophilic cationic protein 
(ECP) was also elevated (38.20   g/l; normal range 1.8–13.3   g/l). 
A parasite screen was negative, and total IgE levels remained nor-
mal. No signs of a haematological disorder were found. The pa-
tient also reported transient urticarial skin changes that devel-
oped after the onset of adalimumab treatment but had resolved 
before clinical examination. After discontinuation of adalimu-
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tion and reporting of potential drug-related side effects is an im-
portant task for clinicians. However, deviations from normal 
laboratory values must be interpreted in a clinical context, and 
not all changes are necessarily of clinical relevance. Here, we re-
port 3 cases of eosinophilia that were temporally associated with 
the administration of TNF antagonists. In 1 of 3 patients, eosin-
ophilia resolved spontaneously during adalimumab treatment. 
Two patients developed de novo eosinophilia, and 1 patient’s pre-
existing eosinophilia worsened. Some cases of eosinophilic pa-
thology associated with TNF-  inhibitors have been observed 
before. Some cases of eosinophilic pathology associated with 
TNF-  inhibitors have been observed before. Etanercept-in-
duced eosinophilic, cellulitis-like reactions and the development 
of Wells syndrome during adalimumab administration have 
been described  [6, 7] . Comparable to our observation, Boura et 
al.  [6] showed that the eosinophil pathology was associated with 
adalimumab. In addition, a patient with no history of atopy de-
veloped asthma during adalimumab therapy  [8] . Vester et al.  [9] 
 reported a woman suffering from acrodermatitis continua of 
Hallopeau who had been treated with adalimumab and devel-
oped a transient blood eosinophilia. Moreover Cancelliere et al. 
[10] could show a connection between infliximab and etanercept 
administration and eosinophilia in a female patient treated for 
rheumatoid arthritis. The patient also developed clinical symp-
toms in terms of a subacute prurigo  [10] . 
 Eosinophilia is stated as a less common side effect ( ! 1%) in the 
product monograph of adalimumab (Humira  ) without provid-
ing further information on the severity or association with other 
clinical or serological findings  [11] . In the eHealthMe database, 
eosinophilia has been observed during adalimumab treatment in 
0.07% of reported side effects  [12] . The majority of patients were 
in the 3rd or 5th decade, most of them were female and in about 
80% the development of eosinophilia occurred within the first
2 years of treatment  [12] . Psoriasis was not in the top underlying 
conditions of these patients, and there was no information about 
the severity of eosinophilia  [12] . 
 We could not identify any other apparent explanation for the 
3 patients’ elevated eosinophil counts. There were no relevant par-
asitological infections or haematological disorders. Two patients 
(No. 1 and 3) had an atopic predisposition (albeit mild) that alone 
would have been unlikely to cause eosinophilia. Patient 1 devel-
oped severe eosinophilia after the introduction of adalimumab; 
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 Fig. 1.  a–c Changes in eosinophil count and PASI values over time, for patients 1, 2 and 3, respectively. Grey 
boxes indicate the periods of treatment with biologicals or methotrexate (MTX). The dashed line shows the cut-
off value of the eosinophilia (700/  l).  d Scatter plot of eosinophil numbers measured during adalimumab versus 
etanercept treatment versus no treatment.  ***  p  ! 0.001; n.s. = non-significant. 
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the condition resolved after discontinuation. Patients 2 and 3 did 
not have eosinophilia prior to therapy. Patient 2 developed eo-
sinophilia after the administration of adalimumab. After the 
withdrawal of adalimumab, the patient’s haematological param-
eters returned to normal values. Patient 3 also developed low-
grade eosinophilia after the administration of etanercept. During 
a treatment-free interval, the eosinophilia disappeared and then 
recurred after the re-introduction of etanercept. After a switch to 
adalimumab, the eosinophil count rose even higher initially and 
then spontaneously normalized. 
 The mechanism of TNF inhibition leading to eosinophilia 
remains unclear. The generation of IgE-class-switched antibod-
ies might lead to IgE-mediated drug hypersensitivity and subse-
quent eosinophilia  [13, 14] . Furthermore, TNF antagonism 
might induce an immune deviation from the Th1 cytokine pat-
tern of psoriasis to the Th2 phenotype  [15] , which can lead to 
eosinophilia and elevated IgE levels  [16] . Quaglino et al. [15] 
could show that patients suffering from psoriasis present an up-
regulation of Th1 and Th17 in the peripheral blood and a down-
regulation of regulatory T cell subsets at baseline. Patients re-
sponding to etanercept administration showed a significant re-
versal of the Th1/Th17 activation indicated by a downmodulation 
in the mRNA expression of the hallmark target genes and cyto-
kines Stat-3/IL-23p19 and Stat-4/IL-12p35, and a concomitant 
upregulation of Th2 and regulatory T cell subsets as shown
by GATA-3, Foxp3/IL-2 and circulating CD4+CD25+ bright 
FoxP3+ T cell subsets in all responsive patients  [15] . This data 
showed the potential involvement of CD4+ T cell modulation in 
the mechanisms of response induction triggered by etanercept 
and possibly other TNF inhibitors. CD4+ T cell modulation can 
be effective in reversing the psoriatic phenotype, as Ghoreschi 
et al. [17] showed with IL-4 therapy in psoriatic patients that in-
duced a marked clinical improvement by upregulation of IL-4-
producing CD4+ T cells.
 The Th1-Th2 balance shift might be the reason that during 
TNF antagonism eosinophilia and PASI showed a reciprocal rela-
tionship as seen in  figure 1 a–c. The more effective and sustained 
the inhibition was, the stronger the eosinophilia. Thus, in some 
patients a pronounced TNF-  blockade may amplify an immune 
deviation to the Th2 phenotype  [18] . Although we did not assay 
serum levels of IL-5 in the isolated cases described here, in the 
future we shall screen for any potential elevation of this cytokine 
 [19] . TNF-  inhibitors might also be able to influence eosinophil 
apoptosis. Mature eosinophils have a lifespan of only 3–5 days and 
are then eliminated by apoptosis  [20, 21] . The observation that 
adalimumab induced more pronounced effects than etanercept 
might reflect adalimumab’s higher potential to reduce the PASI 
and therefore a stronger shift to Th2. Furthermore, different 
structural properties of both drugs may also play a role. Inflix-
imab for example as a monoclonal antibody (but not etanercept) 
has been shown to induce apoptosis in lamina propria T lympho-
cytes in Crohn’s disease  [22] . Thus, the group of TNF-  antago-
nists is heterogeneous, and our findings might express this cir-
cumstance.
 In general, TNF-  antagonists have been found to have dif-
ferential effects on haematopoiesis. A psoriasis patient treated 
with infliximab developed severe neutrophilia  [23] . In a study on 
chronic anaemia of patients with inflammatory bowel disease, 18 
of 27 patients undergoing treatment with infliximab were anae-
mic; most of them had anaemia of chronic disease. Infliximab re-
duced disease activity and improved anaemia in 12 patients. This 
was mediated by an increased production of erythropoietin for the 
Table 1. C linical data of patients 1–3
Patient 1 Patient 2 Patient 3
Gender male female male
Age, years 46 55 24
Disease duration, years 30 13 11
Psoriatic arthritis yes yes no
Atopy yes no yes
Biological used adalimumab, etanercept adalimumab etanercept, adalimumab
PASI before treatment with a biological 11.3 7.7 15.1
Trough PASI during treatment 0.1 0 1.9
Reached PASI75 yes yes yes
Peak eosinophil count, !103/l 1.55 1.48 1.27
Worsening of psoriasis during eosinophilia no no no
Other symptoms or skin changes during eosinophilia urticaria no no
Discontinuation/change of biological yes yes yes
Improvement of eosinophilia after discontinuation yes yes yes
Treatment switch etanercept methotrexate adalimumab
Pathological results by haematologist no no no
Parasitology negative Dientamoeba fragilis negative
Total IgE, kU/l 54.6 24.6 360
Elevated ECP yes yes yes
Elevated tryptase not determined yes no
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degree of anaemia. In vitro infliximab increased the growth of 
erythroid progenitors from the peripheral blood of patients with 
active disease  [24] . Global analysis of haemoglobin levels of 5 phase 
III trials for Crohn’s disease (CHARM trial), rheumatoid arthritis 
(ATTRACT, ASPIRE and START trials) and ankylosing spondy-
litis revealed significant improvement of anaemia by infliximab 
and adalimumab  [25–27] . Etanercept has even been used as a suc-
cessful salvage treatment in severe aplastic anaemia  [28] . 
 On the other hand, blocking TNF-  can also have myelosup-
pressive effects. Infliximab has been used on a series of myelodys-
plastic patients with partial success  [29] . Etanercept led to aplastic 
anaemia complicated by sepsis in a patient with rheumatoid ar-
thritis  [30] .
 Infliximab produced severe neutropenia in a patient with 
rheumatoid arthritis, and rechallenge with infliximab as well as 
etanercept led to the same effect, arguing for a class effect in the 
respective patient  [31] . Another report concerned infliximab-in-
duced thrombocytopenia and neutropenia  [32] . Adalimumab led 
to neutropenia in 2 cases  [33, 34] , in 1 instance associated with 
expansion of the T-large granular lymphocyte compartment  [34] . 
 Taken together, eosinophilia is a rare side effect of anti-TNF-  
treatment. These case reports underline the importance of the 
early identification and reporting of potentially drug-induced 
adverse events. Side effects such as isolated eosinophilia are not 
clinically detectable but can potentially lead to severe organ dam-
age caused by the release of toxic granule proteins (such as eosin-
ophil-derived neurotoxin, ECP, eosinophil peroxidase and eo-
sinophil major basic protein)  [35] . This should be taken into ac-
count when persistent eosinophilia is identified during TNF-  
inhibition.
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